PL2610256T3 - Pochodne pirymidyny jako inhibitory kinaz białkowych - Google Patents

Pochodne pirymidyny jako inhibitory kinaz białkowych

Info

Publication number
PL2610256T3
PL2610256T3 PL13156251.4T PL13156251T PL2610256T3 PL 2610256 T3 PL2610256 T3 PL 2610256T3 PL 13156251 T PL13156251 T PL 13156251T PL 2610256 T3 PL2610256 T3 PL 2610256T3
Authority
PL
Poland
Prior art keywords
protein kinase
kinase inhibitors
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
PL13156251.4T
Other languages
English (en)
Inventor
Jonathan James Hollick
Start Donald Jones
Claire June Flynn
Michael George Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0719038A external-priority patent/GB0719038D0/en
Priority claimed from GB0806844A external-priority patent/GB0806844D0/en
Application filed filed Critical
Publication of PL2610256T3 publication Critical patent/PL2610256T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL13156251.4T 2007-09-28 2008-09-29 Pochodne pirymidyny jako inhibitory kinaz białkowych PL2610256T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0719038A GB0719038D0 (en) 2007-09-28 2007-09-28 Compound
GB0806844A GB0806844D0 (en) 2008-04-15 2008-04-15 Compound

Publications (1)

Publication Number Publication Date
PL2610256T3 true PL2610256T3 (pl) 2016-11-30

Family

ID=40199600

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13156251.4T PL2610256T3 (pl) 2007-09-28 2008-09-29 Pochodne pirymidyny jako inhibitory kinaz białkowych
PL08806455T PL2205603T3 (pl) 2007-09-28 2008-09-29 Pochodne pirymidyny jako inhibitory kinaz białkowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08806455T PL2205603T3 (pl) 2007-09-28 2008-09-29 Pochodne pirymidyny jako inhibitory kinaz białkowych

Country Status (9)

Country Link
US (3) US8563542B2 (pl)
EP (2) EP2610256B1 (pl)
JP (2) JP5410432B2 (pl)
CN (1) CN101878216B (pl)
CA (1) CA2700979C (pl)
ES (2) ES2585110T3 (pl)
PL (2) PL2610256T3 (pl)
RU (2) RU2478100C2 (pl)
WO (1) WO2009040556A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479434T1 (de) 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
EA019487B1 (ru) 2007-09-25 2014-04-30 Такеда Фармасьютикал Компани Лимитед Соединения в качестве ингибиторов plk, фармацевтические композиции, их содержащие, и их применение
EP2610256B1 (en) * 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
CA2728830A1 (en) 2008-06-23 2010-01-21 Jean-Damien Charrier Protein kinase inhibitors
MX346186B (es) 2008-06-23 2017-03-10 Vertex Pharma Inhibidores de proteina cinasas.
PH12015501678B1 (en) 2009-06-17 2022-07-06 Vertex Pharma Inhibitors of influenza viruses replication
JP2013505927A (ja) 2009-09-25 2013-02-21 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピリミジン誘導体の調製方法
KR20120096474A (ko) 2009-09-25 2012-08-30 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
HUE029196T2 (en) 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
BR112013011600B1 (pt) 2010-11-10 2022-01-11 Genentech, Inc Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
EP3388436B1 (en) 2013-03-15 2020-08-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
JP6615755B2 (ja) 2013-11-13 2019-12-04 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルスの複製の阻害剤
AU2014348752C1 (en) 2013-11-13 2019-11-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CN106029653A (zh) 2014-01-31 2016-10-12 达纳-法伯癌症研究所股份有限公司 二氨基嘧啶苯砜衍生物及其用途
KR101517414B1 (ko) * 2014-04-24 2015-05-04 고려대학교 산학협력단 염증성 질환의 예방 또는 치료용 약학 조성물
MX2017001756A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de diazepano y sus usos.
US10011630B2 (en) 2014-12-16 2018-07-03 Invivogen Cyclic dinucleotides for cytokine induction
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CR20180199A (es) 2015-09-11 2018-05-25 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩並三唑並二氮雜環庚三烯及其用途
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
RU2742035C2 (ru) 2015-11-25 2021-02-01 Дана-Фарбер Кэнсер Инститьют, Инк. Бивалентные ингибиторы бромодоменов и пути их применения
MX387025B (es) * 2016-03-04 2025-03-19 Anhui New Star Pharmaceutical Dev Co Ltd Compuestos de anillo de siete miembros de pirimidina
US11155556B2 (en) * 2016-04-07 2021-10-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders
IL274406B2 (en) * 2017-11-02 2024-04-01 Calico Life Sciences Llc Combined pressure pathway modulators
EP3704115A1 (en) 2017-11-02 2020-09-09 Calico Life Sciences LLC Modulators of the integrated stress pathway
ES3047933T3 (en) * 2019-08-16 2025-12-05 Cyclacel Pharmaceuticals Inc Process for the preparation of a pyrimidino-diazepine derivative
PL4013503T3 (pl) * 2019-08-16 2025-09-01 Cyclacel Pharmaceuticals, Inc. Postacie krystaliczne pochodnej pirymidyno-diazepiny
AU2020356484A1 (en) * 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
CN119365489A (zh) 2022-04-08 2025-01-24 印希比生物科学有限公司 Dr5激动剂与plk1抑制剂或cdk抑制剂组合疗法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117635D0 (en) 1991-08-15 1991-10-02 British Telecomm Phase shifter
GB0302220D0 (en) 2003-01-30 2003-03-05 Cyclacel Ltd Use
WO2004076454A1 (de) * 2003-02-26 2004-09-10 Boehringer Ingelheim Pharma Gmbh & Co Kg Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US8710009B2 (en) 2004-05-26 2014-04-29 The Texas A&M University System HSP20 inhibits amyloidogenesis and neurotoxicity
AU2005294575B2 (en) * 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
JP5204650B2 (ja) 2005-06-24 2013-06-05 イーライ リリー アンド カンパニー アンドロゲン受容体調節物質として有用なテトラヒドロカルバゾール誘導体
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
ATE479434T1 (de) * 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
KR101157848B1 (ko) * 2007-03-22 2012-07-11 다케다 야쿠힌 고교 가부시키가이샤 Ｐｌｋ１ 저해제로서 유용한 치환된 피리미도디아제핀
EA019487B1 (ru) * 2007-09-25 2014-04-30 Такеда Фармасьютикал Компани Лимитед Соединения в качестве ингибиторов plk, фармацевтические композиции, их содержащие, и их применение
EP2610256B1 (en) 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2010083505A1 (en) 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
GB201205752D0 (en) 2012-03-30 2012-05-16 Cyclacel Ltd Treatment

Also Published As

Publication number Publication date
WO2009040556A1 (en) 2009-04-02
EP2205603B1 (en) 2014-01-15
US9133199B2 (en) 2015-09-15
US9493471B2 (en) 2016-11-15
CA2700979C (en) 2017-06-20
ES2585110T3 (es) 2016-10-03
CA2700979A1 (en) 2009-04-02
RU2478100C2 (ru) 2013-03-27
JP5410432B2 (ja) 2014-02-05
US20140066436A1 (en) 2014-03-06
EP2610256A1 (en) 2013-07-03
PL2205603T3 (pl) 2014-07-31
US8563542B2 (en) 2013-10-22
HK1146042A1 (en) 2011-05-13
EP2205603A1 (en) 2010-07-14
CN101878216B (zh) 2013-07-10
RU2010116759A (ru) 2011-11-10
JP2014076994A (ja) 2014-05-01
RU2623221C2 (ru) 2017-06-23
US20110046093A1 (en) 2011-02-24
EP2610256B1 (en) 2016-04-27
CN101878216A (zh) 2010-11-03
US20150344486A1 (en) 2015-12-03
ES2457394T3 (es) 2014-04-25
HK1187895A1 (en) 2014-04-17
RU2013108456A (ru) 2014-09-10
JP2010540509A (ja) 2010-12-24
JP5863196B2 (ja) 2016-02-16

Similar Documents

Publication Publication Date Title
PL2610256T3 (pl) Pochodne pirymidyny jako inhibitory kinaz białkowych
HUS1900014I1 (hu) Proteinkináz inhibitorok
IL210124A0 (en) Pyrimidine derivatives as kinase inhibitors
EP2200436A4 (en) SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER
ZA201004243B (en) Benzofuropyrimidinones as protein kinase inhibitors
ZA201201703B (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
PL2193133T3 (pl) Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
IL202835A0 (en) Pyrimidine derivatives useful as raf kinase inhibitors
IL196554A0 (en) Heteroaryl derivatives as protein kinase inhibitors
HRP20130796T1 (en) Pyrimidine derivatives used as pi-3 kinase inhibitors
PL2203449T3 (pl) Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej
PL2197880T3 (pl) Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL210073A0 (en) Protein kinase inhibitors
IL210069A0 (en) Protein kinase inhibitors
PL2231642T3 (pl) Pirymidyny jako inhibitory kinazy
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
HK1150829A (en) Pyrimidine derivatives as kinase inhibitors
GB0715470D0 (en) IKK- serine-threonine protein kinase inhibitors
HK1134814A (en) Benzofuropyrimidinones as protein kinase inhibitors
GB0807642D0 (en) IKK- serine-threonine protein kinase inhibitors